ArticleCardiorenal medicine2018
Plasma Level of Retinol-Binding Protein 4, N-Terminal proBNP and Renal Function in Older Patients Hospitalized for Heart Failure.
Article in Cardiorenal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Retinol-binding Protein 4 as a Predictor of Cardiovascular Events after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.Journal of atherosclerosis and thrombosis · 2026Article
- The Potential Role of Retinol-Binding Protein 4 in Heart Failure: A Review.Reviews in cardiovascular medicine · 2025Review
- Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure.Biomedicines · 2025Review
- Usefulness of Retinol-Binding Protein in Predicting Mortality in Patients With Chronic Liver Disease.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Adipokines and Their Role in Heart Failure: A Literature Review.The Journal of innovations in cardiac rhythm management · 2023Review
- Superoxide dismutase as a protective factor for microalbuminuria in hypertensive patients.Scientific reports · 2022Article
- Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Elevated Serum Retinol Binding Protein 4 is Associated with the Risk of Diabetic Cardiomyopathy.Reviews in cardiovascular medicine · 2022Article
- Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology.International journal of molecular sciences · 2022Article
- Correlation of serum RBP4 level with oxidative stress and unstable carotid plaque in patients with cerebral infarction.Translational neuroscience · 2022Article
- Adipokine Retinol Binding Protein 4 and Cardiovascular Diseases.Frontiers in physiology · 2022Review
- Association Between Circulating Retinol-Binding Protein 4 and Adverse Cardiovascular Events in Stable Coronary Artery Disease.Frontiers in cardiovascular medicine · 2022Article
- Relationship between oxidative stress and nuclear factor-erythroid-2-related factor 2 signaling in diabetic cardiomyopathy (Review).Experimental and therapeutic medicine · 2021Review
- Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease.Journal of healthcare engineering · 2021Article
- Serum retinol-binding protein 4 as a predictor of cardiovascular events in elderly patients with chronic heart failure.ESC heart failure · 2020Article
- New insights into different adipokines in linking the pathophysiology of obesity and psoriasis.Lipids in health and disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimElevated plasma concentration of retinol-binding protein 4 (RBP4) has recently emerged as a potential new risk factor for cardiovascular diseases, including hypertension (HT) and coronary artery disease (CAD). Limited data suggest that RBP4 promotes inflammatory damage to cardiomyocytes and participates in the development of heart failure (HF). This study aimed to analyze the relationship between concentrations of plasma RBP4 and serum N-terminal proBNP (NT-proBNP), a powerful biomarker of left ventricle dysfunction, in the older Polish population.
methodsThe study sample consisted of 2,826 (1,487 men) participants of the PolSenior study, aged 65 years and older, including a subgroup hospitalized for HF (n = 282). In all subjects, plasma concentrations of RBP4, interleukin-6 (IL-6), serum level of NT-proBNP, and hs-CRP were measured. Additionally, BMI, estimated glomerular filtration rate (eGFR), and HOMA-IR were calculated. The prevalence of HT, CAD, atrial fibrillation (AF), and medication were considered as potential confounders.
resultsSimilar RBP4 levels were found in subjects with NT-proBNP < 125 and ≥125 ng/mL, with and without AF, and in the subgroups hospitalized for HF with and without AF. Regression analysis revealed no association between log10(NT-proBNP) and log10(RBP4). Plasma levels of RBP4 were increased by HT occurrence and diuretic therapy, while diminished with regard to female gender, age, eGFR values, AF, and IL-6 levels.
conclusionOur results show that RBP4 is affected by GFR but cannot be considered as an independent biomarker of heart muscle dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.